Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
Authors:
Open Access
- 31 March 2014
- journal article
- Published by Impact Journals, LLC in Oncoscience
- Vol. 1 (3) , 216-228
Abstract
Tumor hypoxia, a feature of many solid tumors including ovarian cancer, is associated with resistance to therapies. We previously demonstrated that hypoxic exposure results in increased expression of phosphorylated signal transducer and activator of transcription 3 (pSTAT3). We hypothesized the activation of STAT3 could lead to chemotherapeutic resistance in ovarian cancer cells in hypoxic conditions. In this study, we demonstrate the level of pSTAT3 Tyr705 is increased in the hypoxic regions of human epithelial ovarian cancer (EOC) specimens, as determined by HIF-1α and CD-31 staining. In vitro mutagenesis studies proved that pSTAT3 Tyr705 is necessary for cell survival and proliferation under hypoxic conditions. In addition, we show that S1PR1, a regulator of STAT3 transcription via the JAK/STAT pathway, is highly expressed in hypoxic ovarian cancer cells (HOCCs). Knock down of S1PR1 in HOCCs reduced pSTAT3 Tyr705 levels and was associated with decreased cell survival. Treatment of HOCCs with the STAT3 inhibitor HO-3867 resulted in a rapid and dramatic decrease in pSTAT3 Tyr705 levels as a result of ubiquitin proteasome degradation. STAT3-target proteins Bcl-xL, cyclin D2 and VEGF showed similar decreases in HO-3867 treated cells. Taken together, these findings suggest that activation of STAT3 Tyr705 promotes cell survival and proliferation in HOCCs, and that S1PR1 is involved in the initiation of STAT3 activation. Targeting hypoxia-mediated STAT3 activation represents a therapeutic option for ovarian cancer and other solid tumors.Keywords
This publication has 34 references indexed in Scilit:
- Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively‐activated Stat3 signaling associated with apoptosis of human pancreatic cancer cellsMolecular Oncology, 2012
- Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cellsMolecular Oncology, 2012
- Synthesis of N-Substituted 3,5-Bis(arylidene)-4-piperidones with High Antitumor and Antioxidant ActivityJournal of Medicinal Chemistry, 2011
- A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical TranslationOncotarget, 2011
- The role of hypoxia inducible factor-1alpha in gynecological cancerCritical Reviews in Oncology/Hematology, 2011
- Inhibiting aberrant Stat3 function with molecular therapeuticsAnti-Cancer Drugs, 2011
- STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumorsNature Medicine, 2010
- HO-3867, a Synthetic Compound, Inhibits the Migration and Invasion of Ovarian Carcinoma Cells through Downregulation of Fatty Acid Synthase and Focal Adhesion KinaseMolecular Cancer Research, 2010
- Identification of a Survival-independent Metastasis-enhancing Role of Hypoxia-inducible Factor-1α with a Hypoxia-tolerant Tumor Cell LineJournal of Biological Chemistry, 2010
- STAT3 Ubiquitylation and Degradation by Mumps Virus Suppress Cytokine and Oncogene SignalingJournal of Virology, 2003